Quadrant Capital Group’s Pacific Biosciences PACB Stock Holding History

Quadrant Capital Group’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$851	Sell	644 -1,910	-75%	-$3.42K	﹤0.01%	2600
2025 Q4	$4.78K	Buy	2,554 +1,189	+87%	+$2.29K	﹤0.01%	2385
2025 Q3	$1.75K	Sell	1,365 -10,651	-89%	-$14.4K	﹤0.01%	2491
2025 Q2	$14.9K	Buy	12,016 +10,344	+619%	+$11.9K	﹤0.01%	1335
2025 Q1	$1.97K	Sell	1,672 -1,896	-53%	-$2.91K	﹤0.01%	2516
2024 Q4	$6.53K	Buy	3,568 +3,096	+656%	+$6.04K	﹤0.01%	2250
2024 Q3	$803	Sell	472 -139	-23%	-$228	﹤0.01%	2621
2024 Q2	$838	Buy	611 +82	+16%	+$166	﹤0.01%	2580
2024 Q1	$1.98K	Buy	+529	New	+$3.1K	﹤0.01%	2513
2021 Q2	–	Sell	-20	Closed	-$1K	–	2516
2021 Q1	$1K	Buy	+20	New	+$700	﹤0.01%	2266
2018 Q1	–	Sell	-354	Closed	–	–	2198
2017 Q4	$0	Hold	354	–	–	﹤0.01%	2147
2017 Q3	$1K	Hold	354	–	–	﹤0.01%	2000
2017 Q2	$0	Buy	+354	New	+$1.43K	﹤0.01%	2003

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Quadrant Capital Group's PACB Position: Q1 2026 in Review

Quadrant Capital Group reduced its Pacific Biosciences (PACB) stake by 75% in Q1 2026, selling an estimated $3.42K and leaving 644 shares worth $851. The position accounts for ﹤0.01% of the portfolio, ranked #2600.

Quadrant Capital Group first reported a position in PACB in Q2 2017 and has held it in 13 quarters since. The position peaked at $14.9K in Q2 2025. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

Quadrant Capital Group held 644 shares of Pacific Biosciences worth $851 as of Q1 2026.
Quadrant Capital Group sold 1,910 Pacific Biosciences shares in Q1 2026, an estimated $3.42K.
Pacific Biosciences made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #2600 holding.
Quadrant Capital Group first reported a position in Pacific Biosciences in Q2 2017 and has held it in 13 quarters since.
Quadrant Capital Group's Pacific Biosciences position peaked at $14.9K in Q2 2025.
229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.